Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. Trade Rep’s IP Report: China Always Improving, But Never Enough

This article was originally published in PharmAsia News

Executive Summary

For the past 20 years, the Office of the U.S. Trade Representative has released an annual Special 301 Report on the "adequacy and effectiveness of intellectual property rights protection by U.S. trading partners," and every year it seems to say that despite improvement, China's IP protection system remains a concern

You may also be interested in...



Forced Technology Transfer Hinders Innovation In China – USTR

China still has major intellectual property enforcement problems that unfairly disadvantage U.S. IP rights holders in the country.

Sanofi Asks Thailand To Review Compulsory Licensing Policy

Sanofi-Aventis sent a request to the previous Thai Minister of Commerce Mingkwan Sangsuwan to review the process of compulsory licensing on patented drugs, Graham Almond, Sanofi-Aventis Thailand general manager told PharmAsia News.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest News
UsernamePublicRestriction

Register

SC071685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel